Kiniksa Pharmaceuticals International, plc
KNSA
Classement en actions
#2960
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Prix de l'action
$79.38
Capitalisation boursière
$6.19B
Changement (1 jour)
1.00%
Changement (1 an)
105.43%
Pays
GB
Échange Kiniksa Pharmaceuticals International, plc (KNSA)
Catégorie
Healthcare
EPS pour Kiniksa Pharmaceuticals International, plc (KNSA)
EPS au June 2026 TTM : $1.07
Selon les derniers rapports financiers et le cours de l'action de Kiniksa Pharmaceuticals International, plc, l’EPS actuel de la société (TTM) est de $1.07. À la fin de 2023, la société avait un EPS de $0.20 une diminution par rapport à celui de 2022, qui était de $2.64.
Historique de l'EPS de Kiniksa Pharmaceuticals International, plc de 2016 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $1.07 | -278.33% |
| 2024 | $-0.60 | -400.00% |
| 2023 | $0.20 | -92.42% |
| 2022 | $2.64 | -214.78% |
| 2021 | $-2.30 | -11.88% |
| 2020 | $-2.61 | -12.71% |
| 2019 | $-2.99 | -14.33% |
| 2018 | $-3.49 | 74.50% |
| 2017 | $-2.00 | 170.27% |
| 2016 | $-0.74 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $2.41 | 125.23% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.52 | -51.40% |
US
|
